MA41975B1 - Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer - Google Patents

Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer

Info

Publication number
MA41975B1
MA41975B1 MA41975A MA41975A MA41975B1 MA 41975 B1 MA41975 B1 MA 41975B1 MA 41975 A MA41975 A MA 41975A MA 41975 A MA41975 A MA 41975A MA 41975 B1 MA41975 B1 MA 41975B1
Authority
MA
Morocco
Prior art keywords
aminohydrothiazine
fusible
alzheimer
disease
useful
Prior art date
Application number
MA41975A
Other languages
English (en)
Inventor
Simon James Richards
Adam Jan Sanderson
David Michael Remick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41975B1 publication Critical patent/MA41975B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C07C309/31—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups by alkyl groups containing at least three carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La présente invention concerne un composé de formule (i) : ou un sel pharmaceutiquement acceptable de celui-ci.
MA41975A 2015-04-29 2016-04-22 Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer MA41975B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154242P 2015-04-29 2015-04-29
PCT/US2016/028896 WO2016176118A1 (fr) 2015-04-29 2016-04-22 Dérivés d'aminohydrothiazine fusionnés avec du tétrahydrofurane utiles dans le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
MA41975B1 true MA41975B1 (fr) 2020-01-31

Family

ID=55861291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41975A MA41975B1 (fr) 2015-04-29 2016-04-22 Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer

Country Status (40)

Country Link
US (1) US10011610B2 (fr)
EP (1) EP3288949B1 (fr)
JP (2) JP2017515831A (fr)
KR (1) KR101979534B1 (fr)
CN (1) CN107531728B (fr)
AR (1) AR104241A1 (fr)
AU (1) AU2016254980B2 (fr)
BR (1) BR112017020180A2 (fr)
CA (1) CA2981091A1 (fr)
CL (1) CL2017002651A1 (fr)
CO (1) CO2017010725A2 (fr)
CR (1) CR20170433A (fr)
CY (1) CY1122375T1 (fr)
DK (1) DK3288949T3 (fr)
DO (1) DOP2017000240A (fr)
EA (1) EA032293B1 (fr)
EC (1) ECSP17071769A (fr)
ES (1) ES2765646T3 (fr)
GT (1) GT201700227A (fr)
HK (1) HK1243709A1 (fr)
HR (1) HRP20192237T1 (fr)
HU (1) HUE047160T2 (fr)
IL (1) IL254252A0 (fr)
MA (1) MA41975B1 (fr)
MD (1) MD3288949T2 (fr)
ME (1) ME03660B (fr)
MX (1) MX2017013694A (fr)
MY (1) MY180727A (fr)
NZ (1) NZ735249A (fr)
PE (1) PE20180048A1 (fr)
PH (1) PH12017501955A1 (fr)
PL (1) PL3288949T3 (fr)
PT (1) PT3288949T (fr)
RS (1) RS59729B1 (fr)
SG (1) SG11201708003WA (fr)
SI (1) SI3288949T1 (fr)
SV (1) SV2017005547A (fr)
TN (1) TN2017000448A1 (fr)
TW (1) TWI619719B (fr)
WO (1) WO2016176118A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
US11559528B2 (en) * 2019-09-05 2023-01-24 The Cleveland Clinic Foundation BACE1 inhibition for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008100165A (ru) 2005-06-14 2009-07-20 Шеринг Корпорейшн (US) Ингибиторы аспартильных протеаз
UA101352C2 (uk) 2008-01-18 2013-03-25 Ейсей Р Енд Д Менеджмент Ко., Лтд. Конденсоване похідне амінодигідротіазину
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
NZ591878A (en) 2008-09-30 2012-06-29 Eisai R&D Man Co Ltd Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071057A1 (fr) 2009-12-09 2011-06-16 塩野義製薬株式会社 Composition pharmaceutique pour le traitement ou la prévention de la maladie d'alzheimer contenant un dérivé hétérocyclique contenant du soufre
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
JPWO2012147762A1 (ja) * 2011-04-26 2014-07-28 塩野義製薬株式会社 ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2014015125A1 (fr) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Sels de dérivé aminodihydrothiazine condensé et applications associées
JP2014101354A (ja) * 2012-10-24 2014-06-05 Shionogi & Co Ltd Ｂａｃｅ１阻害作用を有するオキサジン誘導体
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TWI675034B (zh) 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
WO2018031334A1 (fr) 2016-08-11 2018-02-15 Eli Lilly And Company Aminothiazines et leur utilisation en tant qu'inhibiteurs de bace1

Also Published As

Publication number Publication date
TWI619719B (zh) 2018-04-01
JP6777668B2 (ja) 2020-10-28
HUE047160T2 (hu) 2020-04-28
AU2016254980B2 (en) 2018-06-21
MY180727A (en) 2020-12-08
EA032293B1 (ru) 2019-05-31
BR112017020180A2 (pt) 2018-06-12
AU2016254980A1 (en) 2017-09-21
CY1122375T1 (el) 2021-01-27
DK3288949T3 (da) 2020-01-13
CA2981091A1 (fr) 2016-11-03
PT3288949T (pt) 2020-01-16
PL3288949T3 (pl) 2020-06-01
HRP20192237T1 (hr) 2020-03-06
US10011610B2 (en) 2018-07-03
CN107531728A (zh) 2018-01-02
MD3288949T2 (ro) 2020-03-31
CR20170433A (es) 2017-11-07
EP3288949B1 (fr) 2019-11-06
MX2017013694A (es) 2018-03-02
ES2765646T3 (es) 2020-06-10
IL254252A0 (en) 2017-10-31
SI3288949T1 (sl) 2019-12-31
TN2017000448A1 (en) 2019-04-12
SG11201708003WA (en) 2017-10-30
WO2016176118A1 (fr) 2016-11-03
PE20180048A1 (es) 2018-01-15
GT201700227A (es) 2018-11-23
RS59729B1 (sr) 2020-02-28
AR104241A1 (es) 2017-07-05
CL2017002651A1 (es) 2018-04-20
NZ735249A (en) 2018-08-31
KR20170131597A (ko) 2017-11-29
EP3288949A1 (fr) 2018-03-07
TW201710268A (zh) 2017-03-16
SV2017005547A (es) 2018-04-24
DOP2017000240A (es) 2017-11-15
PH12017501955A1 (en) 2018-03-19
ECSP17071769A (es) 2018-02-28
KR101979534B1 (ko) 2019-05-16
US20160318953A1 (en) 2016-11-03
HK1243709A1 (zh) 2018-07-20
ME03660B (fr) 2020-07-20
CN107531728B (zh) 2019-11-19
EA201792109A1 (ru) 2018-03-30
CO2017010725A2 (es) 2018-01-31
JP2017515831A (ja) 2017-06-15
JP2018140987A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
MA43169B1 (fr) Composés héterocycliques en tant qu&#39; inhibiteurs pi3k-gamma
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
EA201990833A1 (ru) Соединение пиридина
EA201691514A1 (ru) Соединения
MY197698A (en) Oxysterols and methods of use thereof
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA39983B1 (fr) Dérivés de carboxamide
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
NZ746906A (en) Oxaborole esters and uses thereof
MA41633B1 (fr) Composés amide en tant qu&#39;agonistes du récepteur 5-ht4
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d&#39;inhibiteurs des bromodomaines
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MA41975B1 (fr) Derives d&#39;aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d&#39;alzheimer
AU2015280874A1 (en) Novel heterocyclic compound
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu&#39;inhibiteur de pde1 humain
PH12016501645A1 (en) Aminopyrazolone derivative
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
MA39432B1 (fr) Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu&#39;inhibiteur de bace